On the development of an interstitial radiation protocol for a multicenter consortium. Experience with permanent low-dose rate and temporary high-dose rate125I implants in 'failed' and 'newly diagnosed' glioblastoma patients

Quality assurance methodology and a possible future adjuvant for therapeutic enhancement

Robert G. Selker, Margaret S. Eddy, Melvin Deutsch, Vincent C. Arena, Peter Burger

Research output: Contribution to journalArticle

Abstract

Three interstitial implant trial groups (one permanent low-dose rate125I and two temporary high-dose rate125I implants) in glioblastoma patients ('newly diagnosed' and 'failed') were compared to non-randomized similar control groups for efficacy. The results formed the basis for the BTCG 87-01 national implant trial. The 'pilot' trial demonstrated: 1) the effectiveness of a temporary high-dose rate125I implant in 'failed' and 'newly diagnosed' patients; 2) the ability of a multicenter consortium to adhere to a standard protocol; 3) a methodology to insure quality assurance; and 4) the possibility of the future adjuvant application of hyperthermia using a single catheter system.

Original languageEnglish (US)
Pages (from-to)141-155
Number of pages15
JournalJournal of Neuro-Oncology
Volume26
Issue number2
DOIs
StatePublished - Nov 1995

Fingerprint

Glioblastoma
Radiation
Fever
Catheters
Control Groups
Therapeutics

Keywords

  • I interstitial implant
  • hyperthermia
  • malignant glioma
  • quality assurance

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

@article{587f6f8d2d124a248e45172db8dde8ab,
title = "On the development of an interstitial radiation protocol for a multicenter consortium. Experience with permanent low-dose rate and temporary high-dose rate125I implants in 'failed' and 'newly diagnosed' glioblastoma patients: Quality assurance methodology and a possible future adjuvant for therapeutic enhancement",
abstract = "Three interstitial implant trial groups (one permanent low-dose rate125I and two temporary high-dose rate125I implants) in glioblastoma patients ('newly diagnosed' and 'failed') were compared to non-randomized similar control groups for efficacy. The results formed the basis for the BTCG 87-01 national implant trial. The 'pilot' trial demonstrated: 1) the effectiveness of a temporary high-dose rate125I implant in 'failed' and 'newly diagnosed' patients; 2) the ability of a multicenter consortium to adhere to a standard protocol; 3) a methodology to insure quality assurance; and 4) the possibility of the future adjuvant application of hyperthermia using a single catheter system.",
keywords = "I interstitial implant, hyperthermia, malignant glioma, quality assurance",
author = "Selker, {Robert G.} and Eddy, {Margaret S.} and Melvin Deutsch and Arena, {Vincent C.} and Peter Burger",
year = "1995",
month = "11",
doi = "10.1007/BF01060220",
language = "English (US)",
volume = "26",
pages = "141--155",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - On the development of an interstitial radiation protocol for a multicenter consortium. Experience with permanent low-dose rate and temporary high-dose rate125I implants in 'failed' and 'newly diagnosed' glioblastoma patients

T2 - Quality assurance methodology and a possible future adjuvant for therapeutic enhancement

AU - Selker, Robert G.

AU - Eddy, Margaret S.

AU - Deutsch, Melvin

AU - Arena, Vincent C.

AU - Burger, Peter

PY - 1995/11

Y1 - 1995/11

N2 - Three interstitial implant trial groups (one permanent low-dose rate125I and two temporary high-dose rate125I implants) in glioblastoma patients ('newly diagnosed' and 'failed') were compared to non-randomized similar control groups for efficacy. The results formed the basis for the BTCG 87-01 national implant trial. The 'pilot' trial demonstrated: 1) the effectiveness of a temporary high-dose rate125I implant in 'failed' and 'newly diagnosed' patients; 2) the ability of a multicenter consortium to adhere to a standard protocol; 3) a methodology to insure quality assurance; and 4) the possibility of the future adjuvant application of hyperthermia using a single catheter system.

AB - Three interstitial implant trial groups (one permanent low-dose rate125I and two temporary high-dose rate125I implants) in glioblastoma patients ('newly diagnosed' and 'failed') were compared to non-randomized similar control groups for efficacy. The results formed the basis for the BTCG 87-01 national implant trial. The 'pilot' trial demonstrated: 1) the effectiveness of a temporary high-dose rate125I implant in 'failed' and 'newly diagnosed' patients; 2) the ability of a multicenter consortium to adhere to a standard protocol; 3) a methodology to insure quality assurance; and 4) the possibility of the future adjuvant application of hyperthermia using a single catheter system.

KW - I interstitial implant

KW - hyperthermia

KW - malignant glioma

KW - quality assurance

UR - http://www.scopus.com/inward/record.url?scp=0029558003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029558003&partnerID=8YFLogxK

U2 - 10.1007/BF01060220

DO - 10.1007/BF01060220

M3 - Article

VL - 26

SP - 141

EP - 155

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -